HK1064668A1 - Polycyclic guanine phosphodiesterase v inhibitors - Google Patents
Polycyclic guanine phosphodiesterase v inhibitorsInfo
- Publication number
- HK1064668A1 HK1064668A1 HK04107396A HK04107396A HK1064668A1 HK 1064668 A1 HK1064668 A1 HK 1064668A1 HK 04107396 A HK04107396 A HK 04107396A HK 04107396 A HK04107396 A HK 04107396A HK 1064668 A1 HK1064668 A1 HK 1064668A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- polycyclic guanine
- phosphodiesterase
- guanine phosphodiesterase
- polycyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31539501P | 2001-08-28 | 2001-08-28 | |
PCT/US2002/027181 WO2003020724A1 (fr) | 2001-08-28 | 2002-08-26 | Inhibiteurs polycycliques de la phosphodiesterase v de la guanine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1064668A1 true HK1064668A1 (en) | 2005-02-04 |
Family
ID=23224209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04107396A HK1064668A1 (en) | 2001-08-28 | 2004-09-24 | Polycyclic guanine phosphodiesterase v inhibitors |
Country Status (13)
Country | Link |
---|---|
US (1) | US6969719B2 (fr) |
EP (1) | EP1421084B1 (fr) |
JP (2) | JP4450365B2 (fr) |
CN (2) | CN1781920A (fr) |
AR (1) | AR036674A1 (fr) |
AT (1) | ATE395349T1 (fr) |
CA (1) | CA2457944C (fr) |
DE (1) | DE60226615D1 (fr) |
ES (1) | ES2302835T3 (fr) |
HK (1) | HK1064668A1 (fr) |
MX (1) | MXPA04001891A (fr) |
PE (1) | PE20030415A1 (fr) |
WO (1) | WO2003020724A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
JP3945985B2 (ja) * | 2000-12-28 | 2007-07-18 | 株式会社リコー | デジタルカメラ装置 |
WO2003013571A1 (fr) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetiques de metallopeptides biologiquement actifs |
EP1421084B1 (fr) * | 2001-08-28 | 2008-05-14 | Schering Corporation | Inhibiteurs polycycliques de la phosphodiesterase v de la guanine |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
US6943171B2 (en) * | 2001-11-09 | 2005-09-13 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase V inhibitors |
CN101538224A (zh) * | 2002-05-31 | 2009-09-23 | 先灵公司 | 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法 |
SI1509525T1 (sl) * | 2002-05-31 | 2006-12-31 | Schering Corp | Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev |
DE10230311A1 (de) * | 2002-07-05 | 2004-01-22 | Degussa Ag | Verfahren zur Katalysator-freien Herstellung von O-Alkyl-N-cyanformimidaten |
PE20050985A1 (es) * | 2003-11-21 | 2005-11-26 | Schering Corp | Formulaciones de inhibidores de la fosfodiesterasa v |
EP1750862B1 (fr) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Composition pharmaceutique contenant de l'irbesartan |
JP2008534505A (ja) * | 2005-03-25 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | テストステロンサプリメントおよび5アルファ−レダクターゼインヒビターによる男性の治療方法 |
CN103467471A (zh) | 2005-06-06 | 2013-12-25 | 武田药品工业株式会社 | 有机化合物 |
EP1896076A2 (fr) * | 2005-06-27 | 2008-03-12 | Daniel Drai | Compositions et methodes permettant d'ameliorer la fonction sexuelle |
US20070042957A1 (en) * | 2005-08-19 | 2007-02-22 | Mayo Foundation For Medical Education And Research | Type v phosphodiesterase inhibitors and natriuretic polypeptides |
US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
WO2007070426A2 (fr) * | 2005-12-09 | 2007-06-21 | Mayo Foundation For Medical Education And Research | Dysfonctionnement sexuel |
JP2007290996A (ja) * | 2006-04-24 | 2007-11-08 | Ube Ind Ltd | 4−アミノテトラヒドロピランの製法 |
WO2008063505A1 (fr) | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Composés organiques |
WO2008070095A1 (fr) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Nouvelles utilisations |
PE20090418A1 (es) * | 2007-06-21 | 2009-04-18 | Schering Corp | Derivados de guanina policiclicos y sus metodos de uso |
KR101227738B1 (ko) * | 2007-12-06 | 2013-01-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 유기 화합물 |
US8846693B2 (en) | 2007-12-06 | 2014-09-30 | Intra-Cellular Therapies, Inc. | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones |
EP2367429B1 (fr) | 2008-12-06 | 2017-06-07 | Intra-Cellular Therapies, Inc. | Composés organiques |
GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
EP2367428B1 (fr) | 2008-12-06 | 2016-04-06 | Intra-Cellular Therapies, Inc. | Composés organiques |
MX2011005937A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
MX2011005936A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
WO2010098839A1 (fr) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Inhibiteur de pde 1 pour troubles ophtalmiques |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
EP2461673A4 (fr) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | Nouvelles protéines régulatrices et nouveaux inhibiteurs |
US20120316176A1 (en) * | 2009-12-22 | 2012-12-13 | Deen Tulshian | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF |
WO2011153138A1 (fr) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Composés organiques |
EP2590657A4 (fr) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | Composés organiques |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2012171016A1 (fr) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Composés organiques |
WO2014127331A1 (fr) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Nouvelles utilisations |
MX2015013042A (es) | 2013-03-15 | 2016-05-05 | Intra Cellular Therapies Inc | Compuestos organicos. |
EP3479825B1 (fr) | 2013-03-15 | 2021-02-17 | Intra-Cellular Therapies, Inc. | Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de maladies ou de troubles du snc ou du snp |
US9849132B2 (en) | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US10150774B2 (en) | 2014-09-17 | 2018-12-11 | Intra-Cellular Therapies, Inc. | Compounds and methods |
KR102557603B1 (ko) | 2014-12-06 | 2023-07-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US10105349B2 (en) | 2014-12-06 | 2018-10-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2017172795A1 (fr) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Nouvelles compositions et méthodes |
EP3509589B1 (fr) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Nouvelles utilisations |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1938016A1 (de) | 1969-07-23 | 1971-01-28 | Fischer Ohg Arzneimittelwerk | Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten |
FR2116302A1 (en) | 1970-12-07 | 1972-07-13 | Brun Lab Sa Le | 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity |
DE3779374D1 (en) | 1986-08-28 | 1992-07-02 | Sandoz Ag | Xanthinderivate. |
US5321029A (en) | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
FR2654935B1 (fr) | 1989-11-28 | 1994-07-01 | Lvmh Rech | Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux. |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
ZA914727B (en) | 1990-06-21 | 1992-03-25 | Schering Corp | Polycyclic guanine derivatives |
GB9020959D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
GB9020921D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
ES2148170T3 (es) | 1990-12-21 | 2000-10-16 | Beecham Group Plc | Derivados de xantina. |
GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
GB9226532D0 (en) | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
IL108754A0 (en) * | 1993-02-26 | 1994-06-24 | Schering Corp | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
US6037346A (en) | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
HU230154B1 (hu) | 1997-11-12 | 2015-09-28 | Bayer Intellectual Property Gmbh | Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására |
DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU4501199A (en) | 1998-06-03 | 1999-12-20 | Almirall Prodesfarma S.A. | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors |
US6087362A (en) | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6023640A (en) | 1999-03-29 | 2000-02-08 | Ross; Jesse | Method contributing to obviating male impotency |
US20020091129A1 (en) | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
EP1421084B1 (fr) * | 2001-08-28 | 2008-05-14 | Schering Corporation | Inhibiteurs polycycliques de la phosphodiesterase v de la guanine |
-
2002
- 2002-08-26 EP EP02761506A patent/EP1421084B1/fr not_active Expired - Lifetime
- 2002-08-26 DE DE60226615T patent/DE60226615D1/de not_active Expired - Lifetime
- 2002-08-26 CN CNA2005101248185A patent/CN1781920A/zh active Pending
- 2002-08-26 AR ARP020103195A patent/AR036674A1/es unknown
- 2002-08-26 ES ES02761506T patent/ES2302835T3/es not_active Expired - Lifetime
- 2002-08-26 AT AT02761506T patent/ATE395349T1/de not_active IP Right Cessation
- 2002-08-26 WO PCT/US2002/027181 patent/WO2003020724A1/fr active Application Filing
- 2002-08-26 MX MXPA04001891A patent/MXPA04001891A/es active IP Right Grant
- 2002-08-26 US US10/227,778 patent/US6969719B2/en not_active Expired - Fee Related
- 2002-08-26 CN CNB028167066A patent/CN1315835C/zh not_active Expired - Fee Related
- 2002-08-26 JP JP2003524994A patent/JP4450365B2/ja not_active Expired - Fee Related
- 2002-08-26 CA CA002457944A patent/CA2457944C/fr not_active Expired - Fee Related
- 2002-08-27 PE PE2002000821A patent/PE20030415A1/es not_active Application Discontinuation
-
2004
- 2004-09-24 HK HK04107396A patent/HK1064668A1/xx not_active IP Right Cessation
-
2005
- 2005-08-08 JP JP2005230176A patent/JP2005325138A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE395349T1 (de) | 2008-05-15 |
ES2302835T3 (es) | 2008-08-01 |
CN1315835C (zh) | 2007-05-16 |
CA2457944A1 (fr) | 2003-03-13 |
DE60226615D1 (fr) | 2008-06-26 |
US6969719B2 (en) | 2005-11-29 |
CN1781920A (zh) | 2006-06-07 |
CA2457944C (fr) | 2009-09-29 |
CN1547583A (zh) | 2004-11-17 |
MXPA04001891A (es) | 2004-06-15 |
EP1421084A1 (fr) | 2004-05-26 |
WO2003020724A1 (fr) | 2003-03-13 |
US20030153587A1 (en) | 2003-08-14 |
JP2005325138A (ja) | 2005-11-24 |
JP4450365B2 (ja) | 2010-04-14 |
EP1421084B1 (fr) | 2008-05-14 |
PE20030415A1 (es) | 2003-05-22 |
AR036674A1 (es) | 2004-09-29 |
JP2005502684A (ja) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1064668A1 (en) | Polycyclic guanine phosphodiesterase v inhibitors | |
HK1066546A1 (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | |
PL373301A1 (en) | Phosphodiesterase 4 inhibitors | |
AU9102201A (en) | Xanthine phosphodiesterase v inhibitors | |
PL369728A1 (en) | Pyrrolopyrimidines as phosphodiesterase vii inhibitors | |
AU6117801A (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
DE50304867D1 (en) | Thiazolderivate als phosphodiesterase iv-inhibtoren | |
EP1423390A4 (fr) | Inhibiteurs puriques de phosphodiesterase (pde) 7 | |
HUP0401052A3 (en) | Dna-pk inhibitors | |
HK1068140A1 (en) | Xanthine phosphodiesterase v inhibitor polymorphs | |
AU2003254051A8 (en) | Pyrazolopyrimidines as kinase inhibitors | |
PL351822A1 (en) | Thienopyrimidines as phosphodiesterase inhibitors | |
EP1570847A4 (fr) | Inhibiteurs de phosphodiesterase 10a | |
AU2003244080A1 (en) | Phosphodiesterase inhibitor | |
GB0112802D0 (en) | Pyrimidine derivatives | |
GB0112803D0 (en) | Pyrimidine derivatives | |
EP1374911A4 (fr) | Agents permettant de mesurer la capacite de la pyrimidine a etre metabolisee | |
AU2002326765A1 (en) | Polycyclic guanine phosphodiesterase v inhibitors | |
AU2002350157A1 (en) | Polycyclic guanine derivative phosphodiesterase v inhibitors | |
SI1296981T1 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
AU2002317788A1 (en) | Imidazotriazines for use as phosphodiesterase inhibitors | |
ZA200306119B (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors. | |
GB2405870B (en) | DNA-PK inhibitors | |
AU2002348365A1 (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
GB0120333D0 (en) | New purine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120826 |